Amgen AMGN announced that the FDA has approved its rare disease drug Uplizna (inebilizumab) for a new indication. The ...

Both 40 mg and 80 mg doses of INGREZZA showed substantial improvements in AIMS total scores, with mean baseline scores declining markedly by Week 48. The remission rates were consistent irrespective ...

Results showed that 59.2 percent of patients met the remission threshold, with similar outcomes across both 40 mg and 80 mg doses ... reinforcing INGREZZA's effectiveness as a long-term treatment ...

Neurocrine Biosciences’ Kinect 4 open-label study (NCT02405091) found that 59.2% of patients achieved remission of tardive dyskinesia through once-daily doses of Ingrezza (valbenazine).

Neurocrine (NBIX) presented new data from the long-term, open-label KINECT 4 study demonstrating remission of tardive dyskinesia among the ...

Both 40 mg and 80 mg doses of INGREZZA showed substantial improvements in AIMS total scores, with mean baseline scores declining markedly by Week 48. The remission rates were consistent ...

Both 40 mg and 80 mg doses of INGREZZA showed significant improvements in AIMS total scores, with mean baseline scores of 12.4 (40 mg) and 15.1 (80 mg) decreasing to 2.1 and 2.5, respectively ...